Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPEB-01: Olaparib, Pembrolizumab, and Bevacizumab in BRCA Wild-Type Ovarian Cancer
NCT04361370Phase 2Enrolling by invitation
- Sponsor
- Yonsei University
- Start
- Oct 2020
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib, pembrolizumab and bevacizumab in ovarian cancer, sponsored by Yonsei University. Started Oct 2020; status: enrolling by invitation.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04361370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361370.